Simvastatin decreases the hepatic secretion of very‐low‐density lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: pathophysiological and therapeutic implications

European Journal of Clinical Investigation

Volumn 25, Issue 8, 1995, Pages 559-567

  WATTS, G F ^a   CUMMINGS, M H ^b   UMPLEBY, M ^b   QUINEY, J R ^b   NAOUMOVA, R ^c   THOMPSON, G R ^c   SONKSEN P H ^b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b ST THOMAS HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Apolipoprotein B 100; familial hypercholesterolaemia; hepatic secretion; mevalonic acid; simvastatin; stable isotope

Indexed keywords

APOLIPOPROTEIN B100; CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVALONIC ACID; SIMVASTATIN; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FAMILIAL HYPERCHOLESTEROLEMIA; FEMALE; HUMAN; LIPID BLOOD LEVEL; LIPOGENESIS; MALE; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; VOLUNTEER;

ADULT; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; APOLIPOPROTEINS B; FEMALE; HETEROZYGOTE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERLIPOPROTEINEMIA TYPE II; LIPOPROTEINS, VLDL; LOVASTATIN; MALE; MIDDLE AGED; SIMVASTATIN;

EID: 0029098470     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.1995.tb01746.x     Document Type: Article

References (54)

1. Familial Hypercholesterolaemia
2. Cholesterol can stimulate secretion of apolipoprotein B by cultured human hepatocytes
3. Regulation of apoB secretion from HepG2 cells: evidence for a critical role for cholesteryl ester synthesis in the response to a fatty acid challenge
4. The effect of low‐density‐lipoprotein cholesterol and 25‐hydroxycholesterol on apolipoprotein gene expression in HepG2 cells
5. Increased hepatic secretion of very low‐density‐lipoprotein apolipoprotein B‐100 in heterozygous familial hypercholesterolaemia: a stable isotope study
6. Atherosclerosis: the low‐density lipoprotein receptor hypothesis
7. HMG‐CoA reductase inhibitors for treatment of hypercholesterolaemia
8. Plasma mevalo‐nate as a measure of cholesterol synthesis in man
9. The effects of simvastatin on plasma lipoproteins and cholesterol homeostasis in patients with heterozygous familial hypercholesterolaemia
10. Mevinolin and colestipol stimulate receptor‐mediated clearance of low density lipoproteins from plasma in familial hypercholesterolaemia heterozygotes
11. Role of the liver in the maintenance of cholesterol and low density lipoprotein homeostasis in different animal species, including humans
12. Cholesterol is required for secretion of very‐low‐density lipoprotein by rat liver
13. Cholesterol is required for secretion of very‐low‐density lipoprotein: In vivo studies
14. Suppression of apolipoprotein B production during treatment of cholesteryl ester storage disease with lovastatin
15. Lovastatin therapy in familial dysbetalipoproteinemia: effects on kinetics of apolipoprotein B
16. Pravastatin therapy in primary moderate hypercholesterolaemia: changes in metabolism of apolipoprotein B‐containing lipoproteins
17. Lovastatin therapy reduces low density lipoprotein apoB levels in subjects with combined hyperlipidemia by reducing the production of apoB‐containing lipoproteins: implications for the pathophysiology of apoB production
18. Substrate delivery as a determinant of hepatic apoB secretion
19. Regulation of hepatic secretion of apolipoprotein B‐containing lipoproteins: information obtained from cultured liver cells
20. Effects of simvastatin on apoB metabolism and LDL subfraction distribution
21. Non‐uniform radiolabelling of VLDL apolipoprotein B: implications for the analysis of studies of the kinetics of the metabolism of lipoproteins containing apolipoprotein B
22. Investigation of lipoprotein kinetics using endogenous labelling with stable isotopes
23. Determination of kinetic parameters of apolipoprotein B metabolism using amino‐acids labelled with stable isotopes
24. One year experience in the treatment of familial hypercholesterolaemia with simvastatin
25. Relationship of plasma leucine and alpha‐ketoisocaproate during a L‐(1–13C) leucine infusion in man: a method for measuring human intracellular leucine tracer enrichment
26. Apoprotein composition of very low density lipoproteins of human serum
27. Stable isotopes show a direct relation between VLDL apoB overproduction and serum triglyceride levels and indicate a metabolically and biochemically coherent basis for familial combined hyperlipidaemia
28. Tracer‐to‐tracer ratio for analysis of stable isotope tracer data: link with radioactive kinetic formalism
29. Protein measurement with the Folin phenol reagent
30. Apolipoprotein E polymorphisms and atherosclerosis
31. Quantitation of plasma mevalonic acid using gas chromatography‐electron capture mass spectrometry
32. Acute and chronic effect on cholesterol biosynthesis of LDL‐apheresis with or without concomitant HMGCoA reductase inhibitor therapy
33. Blood volume
34. Mevinolin, an inhibitor of cholesterol synthesis, induces mRNA for low density lipoprotein receptor in livers of hamsters and rabbits
35. Altered apolipoprotein B metabolism in very low density lipoprotein from lovastatin‐treated guinea pigs
36. Estimating the fractional synthetic rate of plasma apolipo‐proteins and lipids from stable isotope data
37. 13C] leucine infusion in normal volunteers
38. ApoB metabolism in familial hypercholesterolaemia. Inconsistencies with the LDL receptor paradigm
39. Inhibition of cholesterol synthesis reduces low‐density‐lipoprotein apoprotein B production without decreasing very‐low‐density‐lipoprotein apoprotein B synthesis in rabbits
40. Regulation of apolipoprotein B production and secretion in response to the change of intracellular cholesteryl ester contents in rabbit hepatocytes
41. Effects of oleate and compactin on the metabolism and secretion of cholesterol and cholesteryl ester by rat hepatocytes
42. Inhibition of hepatic ACAT decreases apoB secretion in miniature pigs fed a cholesterol‐free diet
43. Evidence for a lack of regulation of the assembly and secretion of apolipoprotein B‐containing lipoprotein from Hep G‐2 cells by cholesteryl ester
44. Vastatins inhibit cholesterol ester accumulation in human monocyte‐derived macrophages
45. Requirement for mevalonate in acetylated LDL induction of cholesterol esterification in macrophages
46. Feeding of lovastatin to rats increases the activity of the hepatic mitochondrial outer carnitine palmitoyltransferase
47. Effects of lovastatin therapy on very‐low‐density lipoprotein triglyceride metabolism in subjects with combined hyperlipidaemia: evidence for reduced assembly and secretion of triglyceride‐rich lipoproteins
48. Synthesis and secretion of hepatic apolipoprotein B‐containing lipoproteins
49. Role of acyl‐CoA: cholesterol acyltransferase in cellular cholesterol metabolism
50. Effect of lovastatin on acyl‐CoA: cholesterol O‐acyltransferase (ACAT) activity and the basolateral‐membrane secretion of newly synthesized lipids by CaCo‐2 cells
51. Overproduction of low density lipoproteins associated with coronary artery disease
52. Regression of coronary artery disease as a result of intensive lipid‐lowering therapy in men with high levels of apolipoprotein
53. Dietary fish oil plus lovastatin decreases both VLDL and LDL apoB production in minature pigs
54. Direct correlation between cholesterol synthesis and hepatic secretion of apolipoprotein B‐100 in normolipidaemic subjects